Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease

Summary Extramammary Paget’s disease is a malignant intraepithelial carcinoma, which constitutes less than 1 % of all vulvar malignancies. Surgical resection is the first treatment of choice and standard chemotherapy has not been established for advanced or recurrent disease. Experimental and clinical studies have identified human epidermal growth receptor 2 as a potential therapeutic target. A 63-year-old male was referred for recurrent extramammary Paget’s disease after surgery. Human epidermal growth receptor 2 was shown to be overexpressed and amplified by immunohistochemical analysis and fluorescence in situ hybridization analysis, respectively. After two cycles of trastuzumab monotherapy, all lymph node metastases decreased in size. However, he experienced recurrence in the lymph nodes during the seven courses of trastuzumab. As a subsequent treatment, trastuzumab was administered in combination with docetaxel and pertuzumab; clinical response was sustained for 12 months without significant adverse events.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

Abstract BACKGROUND: Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with programmed cell death protein 1 (PD-1) inhibitors has been associated with risk of developing immune-mediated adverse reactions (IMARs). OBJECTIVES: This review provides nurses with an overview of the safety of PD-1 inhibitors approved by the U.S. Food and Drug Administration for recurrent or metastatic SCCHN following platinum chemotherapy, as well as recommendations for assisting with the diagnosis and management of IMARs. METHODS: PubMed® searches were conducted to iden...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
AbstractThe recent genomic characterization of urothelial carcinoma by the Cancer Genome Atlas Project, made possible by the introduction of high throughput, reduced cost, and sequence analysis, has shed new insights on the biology of advanced disease. In addition, studies on imaging of advanced urothelial carcinoma have widened the knowledge on disease presentation and on pattern of metastatic spread and their correlation with the underlying biology of urothelial carcinoma. The wide range of treatments for advanced urothelial cancer, including combined chemotherapy regimens and immune checkpoint inhibitors, each result in...
Source: Abdominal Imaging - Category: Radiology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): A. Minato, R. Moriya, K. Higashijima, G. Yamasaki, R. Oonishi, I. Tomisaki, N. Fujimoto
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Toripalimab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: 5-fu Sponsor:   First Affiliated Hospital of Zhejiang University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Bladder Mixed Adenocarcinoma;   Bladder Urothelial Carcinoma In Situ;   High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma;   Stage 0a Bladder Cancer AJCC v8;   Stage 0is Bladder Cancer AJCC v8;   Stage I Bladder Cancer AJCC v8 Interventions:   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Biological: MK-7684 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Toripalimab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: 5-fu Sponsor:   First Affiliated Hospital of Zhejiang University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Bladder Mixed Adenocarcinoma;   Bladder Urothelial Carcinoma In Situ;   High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma;   Stage 0a Bladder Cancer AJCC v8;   Stage 0is Bladder Cancer AJCC v8;   Stage I Bladder Cancer AJCC v8 Interventions:   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Biological: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Biological: MK-7684 Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS Our study showed that conservative breast surgery is a reliable therapy for breast cancer patients during pregnancy, with similar DFS and OS compared to nonpregnant patients. PMID: 31725704 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Drugs & Pharmacology | Herceptin | Investigational New Drugs | Study | Taxotere